GFWA
MRVI icon

Grey Fox Wealth Advisors’s Maravai LifeSciences MRVI Stock Holding History

Grey Fox Wealth Advisors’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-7
Closed -$98 – 369
2023
Q1 		$98 Hold
7
– – ﹤0.01% 517
2022
Q4 		$100 Buy
+7
New +$110 ﹤0.01% 389

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Grey Fox Wealth Advisors's MRVI Position: Q2 2023 in Review

Grey Fox Wealth Advisors sold out of Maravai LifeSciences (MRVI) in Q2 2023, closing a stake of 7 shares — an estimated $98 sold.

Grey Fox Wealth Advisors first reported a position in MRVI in Q4 2022 and held it in 2 quarters. The position peaked at $100 in Q4 2022. 221 funds tracked by Wall St. Rank hold MRVI as of Q2 2023.

  • Grey Fox Wealth Advisors reported no remaining Maravai LifeSciences position as of Q2 2023 after selling out during the quarter.
  • Grey Fox Wealth Advisors sold 7 Maravai LifeSciences shares in Q2 2023, an estimated $98.
  • Grey Fox Wealth Advisors first reported a position in Maravai LifeSciences in Q4 2022 and held it in 2 quarters.
  • Grey Fox Wealth Advisors's Maravai LifeSciences position peaked at $100 in Q4 2022.
  • 221 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2023.

Based on Grey Fox Wealth Advisors's 13F filing for Q2 2023, filed 3 Aug 2023.